Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
Treatment duration is individualized based on response, tolerability, and clinical goals
Side effects primarily include gastrointestinal events such as nausea, which can be mitigated using dose-escalation regimens that improve tolerance
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.
It is important to consult with your healthcare provider for personalized guidance
US$ 24.22
US$ 21.79
US$ 28.75
US$ 24.46
US$ 24.09
US$ 28.94
